LIVIVO - Search results -

Search results

Result 1 - 10 of total 76

Search options

Article ; Online: Impact of the Si/Al ratio on the ethanol/water coadsorption on MFI zeolites revealed using original quantitative IR approaches.

Douaihy, Rita Zakhia / Lakiss, Louwanda / El-Roz, Mohamad / Levaque, Yoann / Vimont, Alexandre / Bazin, Philippe

Physical chemistry chemical physics : PCCP

2023 Volume 25, Issue 16, Page(s) 11555–11565

Abstract: Advanced IR vibrational spectroscopic techniques, ...

Abstract	Advanced IR vibrational spectroscopic techniques,
Language	English
Publishing date	2023-04-26
Publishing country	England
Document type	Journal Article
ZDB-ID	1476244-4
ISSN	1463-9084 ; 1463-9076
ISSN (online)	1463-9084
ISSN	1463-9076
DOI	10.1039/d3cp00549f
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Study of the diffusion properties of zeolite mixtures by combined gravimetric analysis, IR spectroscopy and inversion methods (IRIS).

Ait Blal, Abdelhafid / Stosic, Dusan / Bazin, Philippe / Vimont, Alexandre / Travert, Arnaud

Physical chemistry chemical physics : PCCP

2023 Volume 25, Issue 40, Page(s) 27170–27180

Abstract: We report the development of a new method of investigation of the mass transport properties of acidic zeolite-based materials aiming to overcome the limitations of classical approaches. It consists in hyphenating gravimetric analysis and infrared ... ...

Abstract	We report the development of a new method of investigation of the mass transport properties of acidic zeolite-based materials aiming to overcome the limitations of classical approaches. It consists in hyphenating gravimetric analysis and infrared spectroscopy. The former allows assessing the diffusion from the gas phase to all the porosity, while IR allows for selective assessment of diffusion to the zeolite active sites located in the micropores. Furthermore, the data are processed by an original methodology allowing the recovery of the distribution of diffusion domains by inversion of the integral equations describing the uptake curves or the evolution of the infrared spectra. The combination of gravimetric analysis and IR spectroscopy makes it possible to monitor and distinguish diffusion within the various components of the material. The methodology has been applied to the isooctane uptake in the mechanical mixture of FAU and MFI zeolites. Analysis of both gravimetric uptake curves and evolving infrared spectra allows distinguishing and assigning diffusion domains to the H-FAU and H-MFI components of the mixture, with high and low effective diffusion rate constants, respectively. The advantages and limits of the methodology are discussed.
Language	English
Publishing date	2023-10-18
Publishing country	England
Document type	Journal Article
ZDB-ID	1476244-4
ISSN	1463-9084 ; 1463-9076
ISSN (online)	1463-9084
ISSN	1463-9076
DOI	10.1039/d3cp01585h
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Evinacumab and Cardiovascular Outcome in Patients With Homozygous Familial Hypercholesterolemia.

Béliard, Sophie / Saheb, Samir / Litzler-Renault, Stéphanie / Vimont, Alexandre / Valero, René / Bruckert, Éric / Farnier, Michel / Gallo, Antonio

Arteriosclerosis, thrombosis, and vascular biology

2024

Abstract: Background: Patients with homozygous familial hypercholesterolemia (HoFH) remain at very high cardiovascular risk despite the best standard of care lipid-lowering treatment. The addition of evinacumab, an angiopoietin-like protein 3 monoclonal antibody, ...

Abstract	Background: Patients with homozygous familial hypercholesterolemia (HoFH) remain at very high cardiovascular risk despite the best standard of care lipid-lowering treatment. The addition of evinacumab, an angiopoietin-like protein 3 monoclonal antibody, more than halves low-density lipoprotein cholesterol in short-term studies. This study evaluated whether the evinacumab response was durable in the long term and improved cardiovascular outcome. Methods: The OLE ELIPSE HoFH (Open-Label Extension to Evinacumab Lipid Studies in Patients With HoFH) study included newly diagnosed patients and those completing the ELIPSE HoFH trial, on stable lipid-lowering therapy including lipoprotein apheresis but not lomitapide. All patients received evinacumab (15 mg/kg intravenously) every 4 weeks, with no change in concomitant lipid-lowering treatment during the first 6 months. The primary efficacy end points were the mean absolute and percentage changes in low-density lipoprotein cholesterol from baseline to 6 months. A key secondary end point was cardiovascular event-free survival, which was compared with a control HoFH cohort not treated with evinacumab or lomitapide and matched for age, sex, and lipoprotein apheresis, derived from French Registry of Familial hypercholesterolemia. Results: Twelve patients, 5 females and 7 males (12-57 years), were enrolled in 3 centers in France. At 6 months, the mean low-density lipoprotein cholesterol reduction with evinacumab was 3.7 mmol/L or 56% (from 6.5 mmol/L at baseline to 2.8 mmol/L; Conclusions: Real-life, long-term evinacumab adjunctive to lipid-lowering therapy including lipoprotein apheresis led to sustained low-density lipoprotein cholesterol lowering and improved cardiovascular event-free survival of patients with HoFH.
Language	English
Publishing date	2024-05-02
Publishing country	United States
Document type	Journal Article
ZDB-ID	1221433-4
ISSN	1524-4636 ; 1079-5642
ISSN (online)	1524-4636
ISSN	1079-5642
DOI	10.1161/ATVBAHA.123.320609
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1705: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Prognostic models for short-term annual risk of severe complications and mortality in patients living with type 2 diabetes using a national medical claim database.

Vimont, Alexandre / Béliard, Sophie / Valéro, René / Leleu, Henri / Durand-Zaleski, Isabelle

Diabetology & metabolic syndrome

2023 Volume 15, Issue 1, Page(s) 128

Abstract: Objective: Prognostic models in patients living with diabetes allow physicians to estimate individual risk based on medical records and biological results. Clinical risk factors are not always all available to evaluate these models so that they may be ... ...

Abstract	Objective: Prognostic models in patients living with diabetes allow physicians to estimate individual risk based on medical records and biological results. Clinical risk factors are not always all available to evaluate these models so that they may be complemented with models from claims databases. The objective of this study was to develop, validate and compare models predicting the annual risk of severe complications and mortality in patients living with type 2 diabetes (T2D) from a national claims data. Research design and methods: Adult patients with T2D were identified in a national medical claims database through their history of treatments or hospitalizations. Prognostic models were developed using logistic regression (LR), random forest (RF) and neural network (NN) to predict annual risk of outcome: severe cardiovascular (CV) complications, other severe T2D-related complications, and all-cause mortality. Risk factors included demographics, comorbidities, the adjusted Diabetes Severity and Comorbidity Index (aDSCI) and diabetes medications. Model performance was assessed using discrimination (C-statistics), balanced accuracy, sensibility and specificity. Results: A total of 22,708 patients with T2D were identified, with mean age of 68 years and average duration of T2D of 9.7 years. Age, aDSCI, disease duration, diabetes medications and chronic cardiovascular disease were the most important predictors for all outcomes. Discrimination with C-statistic ranged from 0.715 to 0.786 for severe CV complications, from 0.670 to 0.847 for other severe complications and from 0.814 to 0.860 for all-cause mortality, with RF having consistently the highest discrimination. Conclusion: The proposed models reliably predict severe complications and mortality in patients with T2D, without requiring medical records or biological measures. These predictions could be used by payers to alert primary care providers and high-risk patients living with T2D.
Language	English
Publishing date	2023-06-15
Publishing country	England
Document type	Journal Article
ZDB-ID	2518786-7
ISSN	1758-5996
ISSN	1758-5996
DOI	10.1186/s13098-023-01105-x
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France.

Vimont, Alexandre / Leleu, Henri / Durand-Zaleski, Isabelle

The European journal of health economics : HEPAC : health economics in prevention and care

2021 Volume 23, Issue 2, Page(s) 211–223

Abstract: Background: Innovative provider payment methods that avoid adverse selection and reward performance require accurate prediction of healthcare costs based on individual risk adjustment. Our objective was to compare the performances of a simple neural ... ...

Abstract	Background: Innovative provider payment methods that avoid adverse selection and reward performance require accurate prediction of healthcare costs based on individual risk adjustment. Our objective was to compare the performances of a simple neural network (NN) and random forest (RF) to a generalized linear model (GLM) for the prediction of medical cost at the individual level. Methods: A 1/97 representative sample of the French National Health Data Information System was used. Predictors selected were: demographic information; pre-existing conditions, Charlson comorbidity index; healthcare service use and costs. Predictive performances of each model were compared through individual-level (adjusted R-squared (adj-R Results: We included 510,182 subjects alive on 31st December, 2015. Mean annual costs were 1894€ (standard deviation 9326€) (median 393€, IQ range 95€; 1480€), including zero-claim subjects. All models performed similarly after adjustment on demographics. RF model had better performances on other sets of covariates (pre-existing conditions, resource counts and past year costs). On full model, RF reached an adj-R Conclusions: RF should be preferred when the objective is to best predict medical costs. When the objective is to understand the contribution of predictors, GLM was well suited with demographics, conditions and base year cost.
MeSH term(s)	Databases, Factual ; Health Care Costs ; Health Services ; Humans ; Linear Models ; Machine Learning
Language	English
Publishing date	2021-08-09
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2045253-6
ISSN	1618-7601 ; 1618-7598
ISSN (online)	1618-7601
ISSN	1618-7598
DOI	10.1007/s10198-021-01363-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5475: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Treatment of pediatric heterozygous familial hypercholesterolemia 7 years after the EAS recommendations: Real-world results from a large French cohort.

Peretti, Noel / Vimont, Alexandre / Mas, Emmanuel / Lemale, Julie / Reynaud, Rachel / Tounian, Patrick / Poinsot, Pierre / Restier, Liora / Paillard, François / Pradignac, Alain / Pucheu, Yann / Rabès, Jean-Pierre / Bruckert, Eric / Gallo, Antonio / Béliard, Sophie

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie

2024 Volume 31, Issue 3, Page(s) 188–194

Abstract: Background: Heterozygous familial hypercholesterolemia (HeFH) predisposes to premature cardiovascular diseases. Since 2015, the European Atherosclerosis Society has advocated initiation of statins at 8-10 years of age and a low-density lipoprotein ... ...

Abstract	Background: Heterozygous familial hypercholesterolemia (HeFH) predisposes to premature cardiovascular diseases. Since 2015, the European Atherosclerosis Society has advocated initiation of statins at 8-10 years of age and a low-density lipoprotein cholesterol (LDL-C) target of <135 mg/dL. Longitudinal data from large databases on pharmacological management of pediatric HeFH are lacking. Objective: Here, we describe treatment patterns and LDL-C goal attainment in pediatric HeFH using longitudinal real-world data. Methods: This was a retrospective and prospective multicenter cohort study (2015-2021) of children with HeFH, diagnosed genetically or clinically, aged <18 years, and followed up in the National French Registry of FH (REFERCHOL). Data on the study population as well as treatment patterns and outcomes are summarized as mean±SD. Results: We analyzed the data of 674 HeFH children (age at last visit: 13.1 ± 3.6 years; 82.0 % ≥10 years; 52.5 % females) who were followed up for a mean of 2.8 ± 3.5 years. Initiation of lipid-lowering therapy was on average at 11.8 ± 3.0 years of age for a duration of 2.5 ± 2.8 years. At the last visit, among patients eligible for treatment (573), 36 % were not treated, 57.1 % received statins alone, 6.4 % statins with ezetimibe, and 0.2 % ezetimibe alone. LDL-C was 266±51 mg/dL before treatment and 147±54 mg/dL at the last visit (-44.7 %) in treated patients. Regarding statins, 3.3 %, 65.1 %, and 31.6 % of patients received high-, moderate-, and low-intensity statins, respectively. Overall, 59 % of children on statin therapy alone and 35.1 % on bitherapy did not achieve the LDL-C goal; fewer patients in the older age group did not reach the treatment goal. Conclusion: Pediatric patients with FH followed up in specialist lipid clinics in France receive late treatment, undertreatment, or suboptimal treatment and half of them do not reach the therapeutic LDL-C goal. Finding a more efficient framework for linking scientific evidence to clinical practice is needed.
MeSH term(s)	Adolescent ; Child ; Female ; Humans ; Male ; Anticholesteremic Agents/therapeutic use ; Cholesterol, LDL/therapeutic use ; Cohort Studies ; Ezetimibe/therapeutic use ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypercholesterolemia ; Hyperlipoproteinemia Type II/drug therapy ; Hyperlipoproteinemia Type II/epidemiology ; Prospective Studies ; Retrospective Studies
Chemical Substances	Anticholesteremic Agents ; Cholesterol, LDL ; Ezetimibe (EOR26LQQ24) ; Hydroxymethylglutaryl-CoA Reductase Inhibitors
Language	English
Publishing date	2024-03-27
Publishing country	France
Document type	Multicenter Study ; Journal Article
ZDB-ID	1181947-9
ISSN	1769-664X ; 0929-693X
ISSN (online)	1769-664X
ISSN	0929-693X
DOI	10.1016/j.arcped.2024.01.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3942: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals.

Béraud, Guillaume / Maupetit, Jean-Claude / Darras, Audric / Vimont, Alexandre / Blachier, Martin

Infectious diseases and therapy

2021 Volume 11, Issue 1, Page(s) 435–449

Abstract: Introduction: The extended half-life of dalbavancin justifies a once-a-week dosing schedule and is supposed to favour early discharge. These advantages may therefore compensate for the cost of dalbavancin, but no real-life assessment has been conducted ... ...

Abstract	Introduction: The extended half-life of dalbavancin justifies a once-a-week dosing schedule and is supposed to favour early discharge. These advantages may therefore compensate for the cost of dalbavancin, but no real-life assessment has been conducted to date. We aimed to assess the real-life budget impact of dalbavancin through its impact on the length of stay in French hospitals. Methods: A multicentre cohort based on the French registry of dalbavancin use in 2019 was compared to the French national discharge summary database. Lengths of stay and budget impact related to the infection type, the time of introduction of dalbavancin, the type of catheter and patient subgroups were assessed. An early switch was defined when dalbavancin was administered as the first or second treatment and within less than 11 days of hospitalization. Results: A total of 179 patients were identified in the registry, and 154 were included in our study. Dalbavancin was mostly used for bone and joint infections (56.0%), infective endocarditis (19.0%) and acute bacterial skin and skin structure infections (6.0%). When compared to the data for similar patients in the national database, the length of stay was almost always shorter for patients treated with dalbavancin (up to a reduction of 13 days). The budget impact for dalbavancin was heterogeneous but frequently generated savings (up to 2257.0 €). Early switching (within less than 11 days) was associated with savings (or lesser costs), with even greater benefits within 7 days of hospitalization. Patients who required a deep venous catheter as well as the most severe patients benefited the most from dalbavancin. Conclusion: Our study confirms that dalbavancin is associated with early discharge, which can offset its cost and generate savings. The greatest benefit is achieved with an early switch.
Language	English
Publishing date	2021-12-15
Publishing country	New Zealand
Document type	Journal Article
ZDB-ID	2701611-0
ISSN	2193-6382 ; 2193-8229
ISSN (online)	2193-6382
ISSN	2193-8229
DOI	10.1007/s40121-021-00577-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pattern of Clinical Progression Until Metastatic Castration-Resistant Prostate Cancer: An Epidemiological Study from the European Prostate Cancer Registry.

Verry, Camille / Vincendeau, Sébastien / Massetti, Marc / Blachier, Martin / Vimont, Alexandre / Bazil, Marie-Laure / Bernardini, Pauline / Pettré, Ségolène / Timsit, Marc-Olivier

Targeted oncology

2022 Volume 17, Issue 4, Page(s) 441–451

Abstract: Background: Prostate cancer (PCa) is the most frequently diagnosed cancer in men in Europe. The impact of PCa natural history and therapeutic management on the outcomes of castration-resistant prostate cancer patients with metastasis (mCRPC) remains ... ...

Abstract	Background: Prostate cancer (PCa) is the most frequently diagnosed cancer in men in Europe. The impact of PCa natural history and therapeutic management on the outcomes of castration-resistant prostate cancer patients with metastasis (mCRPC) remains unclear. Objective: The objective of this study was to describe retrospectively patterns of clinical progression through diagnosis sequences before the mCRPC stage and to assess how these sequences impacted patients' disease progression and overall survival at mCRPC stage. Patients and methods: Patients with mCRPC were identified from the Prostate Cancer Registry (PCR), an observational study in a real-world setting in 16 countries between 2013 and 2016. Patients were grouped in diagnosis sequences before mCRPC and defined by date of PCa diagnosis, first metastasis, and castration resistance. Distribution of time-to-event variables were estimated using Kaplan-Meier product-limit survival curves for overall survival (OS) and progression-free survival (PFS). Non-adjusted Cox models were conducted for efficacy endpoints (OS, PFS) to estimate hazard ratios between diagnosis sequences. Results: At the end of study, 2859 mCRPC patients were included in this analysis. Among mCRPC four diagnosis sequences were identified: 35% developed metastases (mHSPC) before becoming castration resistant (sequence 1, metachronous mHSPC), 10% developed castration resistance (nmCRPC) before metastases (sequence 2), 27% developed metastases and castration resistance within 4 months (sequence 3) and 28% of patients were de novo mHSPC (sequence 4). Median OS was 17.7 months (interquartile range (IQR): 8.8-29.9) and PFS was 6.4 months (IQR: 3.2-12.0). The univariate analyses showed no correlation between mCRPC patients' OS or PFS and the diagnosis sequence. Conclusion: This large European study describe four different patterns of prostate cancer progression to mCRPC stage. Our results indicate that patient survival becomes comparable after progression to mCRPC, regardless of the diagnosis sequence. Trial registration: ClinicalTrials.gov identifier NCT02236637; registered September 2014.
MeSH term(s)	Humans ; Kaplan-Meier Estimate ; Male ; Proportional Hazards Models ; Prostatic Neoplasms, Castration-Resistant/drug therapy ; Registries ; Retrospective Studies ; Treatment Outcome
Language	English
Publishing date	2022-07-16
Publishing country	France
Document type	Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2222136-0
ISSN	1776-260X ; 1776-2596
ISSN (online)	1776-260X
ISSN	1776-2596
DOI	10.1007/s11523-022-00899-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

Article ; Online: A Scalable Robust Microporous Al-MOF for Post-Combustion Carbon Capture.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)

2024 , Page(s) e2401070

Abstract: Herein, a robust microporous aluminum tetracarboxylate framework, MIL-120(Al)-AP, (MIL, AP: Institute Lavoisier and Ambient Pressure synthesis, respectively) is reported, which exhibits high ... ...

Abstract	Herein, a robust microporous aluminum tetracarboxylate framework, MIL-120(Al)-AP, (MIL, AP: Institute Lavoisier and Ambient Pressure synthesis, respectively) is reported, which exhibits high CO
Language	English
Publishing date	2024-03-25
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2808093-2
ISSN	2198-3844 ; 2198-3844
ISSN (online)	2198-3844
ISSN	2198-3844
DOI	10.1002/advs.202401070
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Ultrasmall Copper Nanoclusters in Zirconium Metal-Organic Frameworks for the Photoreduction of CO

Dai, Shan / Kajiwara, Takashi / Ikeda, Miyuki / Romero-Muñiz, Ignacio / Patriarche, Gilles / Platero-Prats, Ana E / Vimont, Alexandre / Daturi, Marco / Tissot, Antoine / Xu, Qiang / Serre, Christian

Angewandte Chemie (International ed. in English)

2022 Volume 61, Issue 43, Page(s) e202211848

Abstract: Encapsulating ultrasmall Cu nanoparticles inside Zr-MOFs to form core-shell architecture is very challenging but of interest for ... ...

Abstract	Encapsulating ultrasmall Cu nanoparticles inside Zr-MOFs to form core-shell architecture is very challenging but of interest for CO
Language	English
Publishing date	2022-09-23
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2011836-3
ISSN	1521-3773 ; 1433-7851
ISSN (online)	1521-3773
ISSN	1433-7851
DOI	10.1002/anie.202211848
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito